Two clinical trials for the testing of an Alzheimer’s drug, have been canceled due to the lack of prospect of success.

analysis of an independent panel of experts had shown that the tested antibodies Aducanumab does not brake as expected the reduction of intellectual performance, had notified the company Biogen on Thursday.

Biogen had tested the substance for 2017, together with the Japanese pharmaceutical company Eisai for the market introduction. Safety concerns have played for the termination of the studies, no matter, – said Biogen. Hans-Ulrich Demuth Fraunhofer Institute for cell therapy and immunology, commented on the study From this: “Quite simply, It is a Disaster for the whole field.”

dpa

SHARE
Previous articleExplosion in the chemical Park: number of dead rises to 47 – pressure wave raced through the city
Next articleSuspected perpetrators of Utrecht remains in custody
Teodora Torrendo is an investigative journalist and is a correspondent for European Union. She is based in Zurich in Switzerland and her field of work include covering human rights violations which take place in the various countries in and outside Europe. She also reports about the political situation in European Union. She has worked with some reputed companies in Europe and is currently contributing to USA News as a freelance journalist. As someone who has a Masters’ degree in Human Rights she also delivers lectures on Intercultural Management to students of Human Rights. She is also an authority on the Arab world politics and their diversity.

LEAVE A REPLY

Please enter your comment!
Please enter your name here